These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36921715)

  • 21. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Branche AR; Rouphael NG; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Anderson EJ; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Malkin E; Bethony JM; Walsh EE; Graciaa DS; Samaha H; Sherman AC; Walsh SR; Abate G; Oikonomopoulou Z; El Sahly HM; Martin TCS; Kamidani S; Smith MJ; Ladner BG; Porterfield L; Dunstan M; Wald A; Davis T; Atmar RL; Mulligan MJ; Lyke KE; Posavad CM; Meagher MA; Stephens DS; Neuzil KM; Abebe K; Hill H; Albert J; Telu K; Mu J; Lewis TC; Giebeig LA; Eaton A; Netzl A; Wilks SH; Türeli S; Makhene M; Crandon S; Montefiori DC; Makowski M; Smith DJ; Nayak SU; Roberts PC; Beigel JH;
    Nat Med; 2023 Sep; 29(9):2334-2346. PubMed ID: 37640860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
    Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
    Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
    Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine.
    Li W; Zhao T; Tao B; Zhao L; Xiao H; Ding X; Li C; Chen L; Cheng H; Lou Y; Chen Y; Wu C
    Hum Vaccin Immunother; 2023 Aug; 19(2):2264589. PubMed ID: 37846840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients.
    Peled Y; Afek A; Patel JK; Raanani E; Segev A; Ram E; Fardman A; Beigel R; Atari N; Kliker L; Elkader BA; Mandelboim M
    J Heart Lung Transplant; 2023 Aug; 42(8):1054-1058. PubMed ID: 37084801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
    Yau K; Kurtesi A; Qi F; Delgado-Brand M; Tursun TR; Hu Q; Dhruve M; Kandel C; Enilama O; Levin A; Jiang Y; Hardy WR; Yuen DA; Perl J; Chan CT; Leis JA; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Nat Commun; 2023 Sep; 14(1):6041. PubMed ID: 37758707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.
    Park JS; Jeon J; Um J; Choi YY; Kim MK; Lee KS; Sung HK; Jang HC; Chin B; Kim CK; Oh MD; Lee CS
    Infect Chemother; 2024 Mar; 56(1):25-36. PubMed ID: 38014726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
    Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
    Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
    EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Wang LF; Ren EC; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Dec; 23(12):1343-1348. PubMed ID: 37543042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
    Wang Q; Guo Y; Tam AR; Valdez R; Gordon A; Liu L; Ho DD
    Cell Rep Med; 2023 Nov; 4(11):101258. PubMed ID: 37909042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
    Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
    AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.
    Hu J; Liu Y; Liu S; Shu Q; Yang X; Chu K; Qiao Y; Hu Y; Wang K; Pan H
    Front Immunol; 2023; 14():1241153. PubMed ID: 37799724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
    Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
    BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
    Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
    J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.